Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 1/20 | 0.58 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.58 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.58 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.49 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.49 |
| ▸ | ITK | Q08881 | 1/20 | 0.47 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.47 |
| ▸ | GPR183 | P32249 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30339870 | 1.00 | CASP3 (0.58) | CASP3SENP8SENP7SENP6TDP1 | |
| SCHEMBL28555669 | 0.85 | CYP2A6 (0.50) | CASP3SENP8SENP7SENP6TDP1 | |
| SCHEMBL1105989 | 0.85 | HRH3 (0.59) | TDP1HSP90AA1ESR2KDM4EALDH1A1 | |
| SCHEMBL10053488 | 0.84 | CHEK2 (0.49) | CASP3SENP8SENP7SENP6KDM4E | |
| SCHEMBL9372548 | 0.83 | CASP3 (0.42) | CASP3SENP8SENP7SENP6TDP1 | |
| SCHEMBL18569112 | 0.81 | BRD4 (0.54) | CASP3SENP8SENP7SENP6TDP1 | |
| SCHEMBL3922415 | 0.81 | CASP3 (0.54) | CASP3SENP8SENP7SENP6TDP1 | |
| SCHEMBL30460215 | 0.81 | KDM4E (0.61) | TDP1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL5881610 | 0.81 | KDM4E (0.61) | TDP1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL31721323 | 0.79 | CASP3 (0.60) | CASP3SENP8SENP7SENP6TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4376818-B1 | SEROTONIN 5-HT2B INHIBITORY COMPOUNDS | ZOETIS SERVICES LLC (US) | 2025-06-18 | — | — | EP | disclosed |
| US-12209084-B2 | Serotonin 5-HT2B inhibitory compounds | ZOETIS SERVICES LLC (US) | 2025-01-28 | — | — | US | disclosed |
| WO-2024179405-A1 | CLASS OF CINNAMAMIDE DERIVATIVES AND APPLICATION THEREOF | 上海交通大学 | 2024-09-06 | — | — | WO | disclosed |
| CN-118546081-A | Cinnamide derivative and application thereof | 上海交通大学 | 2024-08-27 | — | — | CN | disclosed |
| EP-4376818-A1 | SEROTONIN 5-HT2B INHIBITORY COMPOUNDS | Zoetis Services LLC (US) | 2024-06-05 | — | — | EP | disclosed |
| CN-117729914-A | Serotonin 5-HT2B inhibiting compounds | 硕腾服务有限责任公司 | 2024-03-19 | — | — | CN | disclosed |
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-12-12 | — | — | US | disclosed |
| US-11712438-B2 | Phenyl derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-08-01 | — | — | US | disclosed |
| CN-110678450-B | Isoxazole derivatives as nuclear receptor agonists and uses thereof | 日东制药株式会社 | 2023-06-20 | — | — | CN | disclosed |
| US-20230071039-A1 | SEROTONIN 5-HT2B INHIBITORY COMPOUNDS | ZOETIS SERVICES LLC | 2023-03-09 | — | — | US | disclosed |
| EP-0705832-B1 | Serotonergic modulators | LILLY CO ELI (GB) | 2003-08-13 | — | — | EP | disclosed |
| EP-0539117-B1 | Compounds useful as leukotriene antagonists | LILLY CO ELI (GB) | 1998-03-11 | — | — | EP | disclosed |
| US-5563147-A | CENTRAL NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY (US) | 1996-10-08 | — | — | US | disclosed |
| EP-0705832-A1 | Serotonergic modulators | LILLY INDUSTRIES LIMITED (GB) | 1996-04-10 | — | — | EP | disclosed |
| US-5410061-A | Leukotriene antagonist | LILLY INDUSTRIES LIMITED (GB) | 1995-04-25 | — | — | US | disclosed |
| EP-0539117-A1 | Compounds useful as leukotriene antagonists | LILLY INDUSTRIES LIMITED (GB) | 1993-04-28 | — | — | EP | disclosed |
| EP-0409027-A1 | Indole derivatives, process for their preparation and their use in pharmaceuticals | BAYER AG (DE) | 1991-01-23 | — | — | EP | disclosed |
| US-4493843-A | Indole and indoline carboxylic acid compounds and method of use | MAY & BAKER LIMITED (GB) | 1985-01-15 | — | — | US | disclosed |
| EP-0042298-B1 | INDOLE AND INDOLINE DERIVATIVES | MAY & BAKER LIMITED (GB) | 1984-09-12 | — | — | EP | disclosed |
| EP-0042298-A1 | Indole and indoline derivatives | MAY & BAKER LIMITED (GB) | 1981-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230071039-A1 | SEROTONIN 5-HT2B INHIBITORY COMPOUNDS | HTR2B, HTR1B, HTR1A | CASP3 3732/4885SENP8 4257/4885SENP7 2971/4885 |
| US-11712438-B2 | Phenyl derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | CASP3 2656/4885SENP8 4653/4885SENP7 4512/4885 |
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | CASP3 3451/4885SENP8 4750/4885SENP7 4722/4885 |
| US-12209084-B2 | Serotonin 5-HT2B inhibitory compounds | HTR2B, HTR1B, HTR1A | CASP3 3732/4885SENP8 4257/4885SENP7 2971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.